Trial Profile
An Open Label, Proof of Concept Study to Assess the Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs PRX 106 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Sponsors Protalix Biotherapeutics
- 05 Jun 2018 Status changed from active, no longer recruiting to completed, based on the results presented at the Digestive Disease Week 2018.
- 05 Jun 2018 Results presented at the Digestive Disease Week 2018.
- 05 Jun 2018 Results presented in a Protalix BioTherapeutics media release.